· New NIH study found that around one in seven children under age six with a prior SARS-CoV-2 infection met the probable diagnostic criteria for #LongCOVID
· Pemivibart (Pemgarda), a monoclonal antibody that helps prevent COVID-19, was found to be “well tolerated” and effective in phase 3 clinical trial
· New preprint from researchers in the US & Canada used a model called “Mobius” to classify ME & Long COVID with 97% accuracy, using data from blood

https://thesicktimes.org/2025/06/03/research-updates-june-3/

#ResearchUpdate

· Three recent studies show the harmful effects of misdiagnosis for chronic diseases and conditions
· A new preprint shared in Research Square found a connection between post-exertional malaise (PEM) and microclots, or tiny blood clots that disrupt how oxygen moves through the body
· The Cohen Center for Recovery from Complex Chronic Illness (CoRE) at Mount Sinai in New York is now recruiting for their rapamycin clinical trial for #LongCOVID

https://thesicktimes.org/2025/06/10/research-updates-june-10/

#COVID19 #ResearchUpdate

· Pregnant people infected with SARS-CoV-2 during first trimester more likely to have smaller newborns
· Children with multisystem inflammatory syndrome (MIS-C) triggered by COVID-19 had metabolic disturbances that “mirrored those seen in severe adult #COVID19 patients
· A population-level study from a database in Utah found there was a significant association between a past COVID-19 diagnosis and self-harming in children and adolescents

https://thesicktimes.org/2025/06/17/research-updates-june-17/

#ResearchUpdate

· A new review paper published in Psychiatry and Clinical Neurosciences focuses on how Long COVID impacts the nervous and immune systems
· Another study has found potential biomarkers in the blood of people with myalgic encephalomyelitis (ME)
· The Patient-Led Research Collaborative (PLRC) launched a new clinical trial and research study platform for Long COVID and associated diseases: the PLRC Registry

https://thesicktimes.org/2025/06/24/research-updates-june-24/

#ResearchUpdate #LongCOVID #MECFS

· Scientists found a new antiviral drug prototype that prevented Long COVID in mice and could also help treat the disease
· A recent preprint shared in medRxiv found further evidence of brain damage after COVID-19
· A new clinical trial for myalgic encephalomyelitis (ME) is recruiting in Tokyo, Japan, to test the monoclonal antibody Rituximab

https://thesicktimes.org/2025/07/01/research-updates-july-1/

#ResearchUpdate #COVID19

· The biotech company Invivyd, which makes the #COVID19 monoclonal antibody Pemgarda, announced that it has launched the SPEAR Study Group to explore the drug for #LongCOVID and post-vaccine syndrome (PVS)
· A new study from Taiwan published in Pediatrics and Neonatology found about 14% of children developed Long COVID after being infected with #SarsCoV2
· A new observational study is investigating the relationship between COVID-19 and #Diabetes

https://thesicktimes.org/2025/07/08/research-updates-july-8/

#ResearchUpdate

· A new study in PNAS found elevated oxidative stress was a shared characteristic in both #MECFS and #LongCOVID
· RECOVER-Treating Long COVID, the clinical trials initiative run by the Foundation for the NIAID, has announced that it will hold a second annual hybrid workshop discussing the initiative’s research
· A clinical trial in the U.K. called PHOSP-I is recruiting to test the monoclonal antibody Tocilizumab

https://thesicktimes.org/2025/07/15/research-updates-july-15/

#ResearchUpdate #COVID19

· A treatment for cats with a #COVID19-related infection may help advance #LongCOVID research
· The supplement Oxaloacetate may help reduce fatigue for LC, but it “did not reach statistical significance,” according to a new study at Bateman Horne Center
· A new prospective cohort study in JAMA Oncology of 1,572 participants with cancer found that COVID-19 had a “significant impact” on these patients, incl. hospitalization, treatment disruptions, death

https://thesicktimes.org/2025/07/22/research-updates-july-22/

#ResearchUpdate

· Two studies on potential biomarkers for #MECFS were published this month
· Stellate ganglion blocks, a procedure where an anesthetic is injected into nerves in the neck, may help reduce the severity of some symptoms of #LongCOVID and ME
· An observational study is recruiting 40 people in Boston, Massachusetts to test for defects of air and blood flow in the lungs in people with Long COVID

https://thesicktimes.org/2025/07/29/research-updates-july-29/

#ResearchUpdate #COVID19

· A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children
· “Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames,” said one of the authors of a new study in Nature
· An upcoming at-home clinical trial program for #LongCOVID, run by Scripps Research, is seeking participants

https://thesicktimes.org/2025/08/05/research-updates-august-5/

#ResearchUpdates #COVID19

· People with myalgic encephalomyelitis (#MECFS) have significant genetic differences in their DNA
· A very small clinical trial of the infusion drug BC 007 published in eClinicalMedicine found “significant improvement” in fatigue in people with #LongCOVID
· A phase 2 clinical trial testing the monoclonal antibody sipavibart is recruiting in Fort Lauderdale, Florida

https://thesicktimes.org/2025/08/12/research-updates-august-12/

#ResearchUpdates #COVID19

· A new preprint from the National Institutes of Health (NIH) RECOVER study found that #COVID19 reinfections may increase risk of #LongCOVID by about 35%
· A new review article in Ageing Research Reviews found that persistent infections from viruses, bacteria, fungus, and parasites can accelerate human aging
· A new Long COVID clinical trial to test the immunotherapy drug Anktiva was announced this week by the Chan Soon-Shiong Institute for Medicine

https://thesicktimes.org/2025/08/19/research-updates-august-19/

#ResearchUpdates

· Metformin may help reduce the risk of #LongCOVID, according to two new studies
· A Phase 2 clinical trial is studying the drug vidofludimus calcium (IMU-838) for Long COVID
· The National Institutes of Health’s second RECOVER-Treating Long COVID workshop is happening next week, September 9–10

https://thesicktimes.org/2025/09/02/research-updates-september-2/

#ResearchUpdates #COVID19

· A medium sized study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed #LongCOVID
· In a small case series, a combination of three antivirals was effective in improving symptoms in participants with Long COVID, according to a new preprint
· The Food and Drug Administration (FDA) accepted the drug application of a potential oral therapy for the prevention of #COVID19 following exposure

https://thesicktimes.org/2025/09/09/research-updates-september-9/

#ResearchUpdates

· An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced #LongCOVID, according to a new systematic review
· New funding will help advance a potential low-cost diagnostic test for myalgic encephalomyelitis (#ME)
· The SPEAR study group has proposed a potential Long COVID clinical trial with the company’s next-generation monoclonal antibody, VYD2311

https://thesicktimes.org/2025/09/16/research-updates-september-16/

#COVID19 #ResearchUpdates

· Two recent studies found limitations of the drug Paxlovid for protection from #LongCOVID, contrasting prior studies that suggested the antiviral drug might help prevent the disease
· Long COVID may increase menstrual bleeding, according to a new survey study published in Nature Communications
· A new clinical trial is testing the supplement Mitoquinone in combination with “exercise rehabilitation” (which may be detrimental) for Long COVID

https://thesicktimes.org/2025/09/23/research-updates-september-23/

#ResearchUpdates #COVID19

· Researchers in Spain assessed over 190,000 participants, found that #LongCOVID prevalence was three to 10 times higher in individuals with three or more reported infections
· A new RECOVER study published in JAMA found that olfactory dysfunction, or changes to sense of smell, occurred in people after SARS-CoV-2 infection
· A behavioral trial at Columbia University (LONG-CALM) is assessing a vague “mindfulness intervention” for Long COVID

https://thesicktimes.org/2025/09/30/research-updates-september-30/

#COVID19 #ResearchUpdates

· A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week
· Researchers in Japan may have found a potential biomarker and treatment target for cognitive dysfunction in #LongCOVID
· A new phase 1 clinical trial is currently recruiting to test the GLP-1 agonist drug Liraglutide for Long COVID, multiple sclerosis, and acute leukemia

https://thesicktimes.org/2025/10/07/research-updates-october-7/

#COVID19 #ResearchUpdates

· A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer
· A small study in the Journal of Translation Medicine found a potential blood test for myalgic encephalomyelitis (ME)
· Researchers have developed a device that may be able to accurately measure fibrinaloid microclots in children

https://thesicktimes.org/2025/10/14/research-updates-october-14/

#ResearchUpdates #COVID19 #MECFS

· A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for #LongCOVID
· A white paper from the Patient-Led Research Collaborative assessed Long COVID in India
· Researchers recently critiqued the study design and conclusions of a controversial 2024 study on ME, which asserted that the disease was a result of altered “effort preference” and deconditioning

https://thesicktimes.org/2025/10/21/research-updates-october-21/

#ResearchUpdates #COVID19

· A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in #COVID19.

· A recent paper found that low-dose rapamycin alleviated symptoms of fatigue and post-exertional malaise in people with #MECFS.

· A phase 2 clinical trial is recruiting in Boston, Massachusetts to test the drugs Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) for ME.

https://thesicktimes.org/2025/10/28/research-updates-october-28/

#ResearchUpdates #LongCOVID

· The #German government is cutting millions of euros in #LongCOVID funding
· Large electronic cohort study from Sweden found that 1.4% of people with a documented #COVID19 case were officially diagnosed with Long COVID by medical providers
· Lidia Morawska, Australian scientist who alerted the world that SARS-CoV-2 was airborne, was recently recognized for her work with a prestigious science prize for “pioneering research about the air we breathe"

https://thesicktimes.org/2025/11/04/research-updates-november-4/

#ResearchUpdates

· The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating #LongCOVID
· Scientists are revealing more about microclots and Long COVID. A recent study in the Journal of Medical Virology found a strong association between microclots and net-like structures that some white blood cells (called neutrophils) release to attack pathogens
· A study about #MECFS was retracted by the journal Food Science and Nutrition

https://thesicktimes.org/2025/11/11/research-updates-november-11/

#ResearchUpdates #COVID19

· New mechanistic study in Science Translational Medicine identifies Epstein-Barr virus as a potential trigger of the autoimmune disease systemic #lupus erythematosus
· Michael Peluso of UCSF shared updates on two upcoming #LongCOVID trials:
- One potential trial called COMBAT-LC plans to test the combination of the monoclonal antibody Pemgarda with the antiviral Paxlovid
- The second trial INTERRUPT-LC will test the bladder cancer drug Anktiva

https://thesicktimes.org/2025/11/18/research-updates-november-18/

#ResearchUpdates

· A review paper summarizes the vast global costs of #LongCOVID, it is estimated to have an average annual burden of at least $1 trillion globally per year
· A small study in Nature found SARS-CoV-2 in the organs of fetuses from people who were infected with the virus while pregnant
· The National Institutes of Health’s RECOVER-Treating Long COVID initiative released a draft of its protocol for the low-dose naltrexone trial for people ages 6-25

https://thesicktimes.org/2025/11/25/research-updates-november-25/

#ResearchUpdates #covid19

· Large retrospective cohort study of over 18,000 births found infants exposed to #COVID19 during pregnancy were more likely to have adverse neurodevelopmental diagnoses as 3 years olds
· Another study has found that common diabetes drug metformin may help reduce risk of #LongCOVID
· NIH is recruiting for a small observational study to understand if people with neurological symptoms of Long COVID have inactive [?] remnants of SARS-CoV-2 in their bodies

https://thesicktimes.org/2025/12/02/research-updates-december-2/

#ResearchUpdates

· A new study in the International Journal of Infectious Diseases examines how #COVID19 impacts the immune system
· German government announced just over €500 million ($582 million USD) in funding for infection-associated diseases, including #LongCOVID & #MECFS
· A preprint using data from the DecodeME study found more than 250 genes associated with ME, 76 of which were shared with Long COVID

https://thesicktimes.org/2025/12/09/research-updates-december-9/

#researchupdates

· New study in Cureus found veterans diagnosed with #LongCOVID at 34% higher risk of visiting emergency department 6 months after infection
· “Our data demonstrate that [LC] is characterized by chronic inflammation, immune exhaustion, & metabolic dysregulation,” scientists conclud in new study published in Nature Immunology
· U.K. charity ME Association awards £1.1 million in funding to the Imperial College to study immunological profiles of LC & #MECFS

https://thesicktimes.org/2025/12/16/research-updates-december-16/

#ResearchUpdates

· Two recent studies state that #LongCOVID is an occupational disease.
· Vanderbilt researchers are conducting an immune profiling study on people with Long COVID and postural orthostatic tachycardia syndrome (#POTS)
· A new phase two remote clinical trial was recently announced for myalgic encephalomyelitis (ME) #MECFS

https://thesicktimes.org/2025/12/23/research-updates-december-23/

#ResearchUpdates

· 43% of Latino people reported symptoms of #LongCOVID in a new survey study published in Journal of General Internal Medicine
· A case series for Long COVID using a combination of Paxlovid, valacyclovir (Valtrex) and celecoxib (Celebrex), was recently published in Frontiers of Immunology
· A new phase II clinical trial for Long COVID was recently announced in the Netherlands

https://thesicktimes.org/2026/01/06/research-updates-january-6/

#ResearchUpdates #COVID

· A large, electronic health records study published in JAMA Internal Medicine estimated that over 100,000 Americans died each year between 2022 and 2024 from #COVID19
· A new study published in Molecular & Cellular Proteomics found further evidence of abnormalities in post-exertional malaise #PEM
· A small phase two clinical trial is testing #Ketamine for #LongCOVID fatigue and cognitive function

https://thesicktimes.org/2026/01/13/research-updates-january-13/

#ResearchUpdates #TheSickTimes

· A new study in eBioMedicine found neurological #LongCOVID symptoms were associated with increased pTau-181 levels, a marker of brain inflammation tied to Alzheimer’s disease
· A new “state-of-the-art” review on #POTS highlighted that the multisystemic condition is disabling, causes societal & economic withdrawal
· A phase II clinical trial testing efficacy & safety Uplizna (Inebilizumab) in LC & #MECFS recently announced by German Ministry of Research

https://thesicktimes.org/2026/01/20/research-updates-january-20/

#ResearchUpdates

· A large prospective cohort study published in Infectious Diseases found that a majority of people with #LongCOVID did not recover
· Some researchers in Australia are getting a small boost in Long COVID funding
· The biotech company Invivyd is advancing research of a #COVID19 monoclonal antibody called VYD2311, designed to improve upon the currently-available Pemgarda

https://thesicktimes.org/2026/01/27/research-updates-january-27/

#ResearchUpdates

· The Food and Drug Administration (FDA) has granted expanded access to the stem cell infusion RegeneCyte for #LongCOVID
· Long COVID isn’t being consistently captured around the world due to differences in sociological factors, diagnostic tools, and healthcare access
· A phase two trial for Long COVID-associated postural orthostatic tachycardia syndrome (#POTS) is testing a product called 2-hydroxybenzylamine (2-HOBA)

https://thesicktimes.org/2026/02/03/research-updates-february-3/

#ResearchUpdates #COVID

· A large study recently connected “chronic absenteeism” to pediatric #LongCOVID, further disproving the “immunity debt” talking points from pundits earlier in the pandemic
· A small mechanistic study in Brain, Behavior, & Immunity – Health found that immunoglobulin G (IgG), isolated from people with #MECFS, can destroy mitochondria in endothelial cells
· ADDRESS-LC has opened two more study sites: a new one in California and one in Connecticut

https://thesicktimes.org/2026/02/10/research-updates-february-10/

#ResearchUpdates

· New review in Dovepress states that #LongCOVID, #MECFS & #POTS should be classified as neuroimmune disorders.
· Wearable activity tracker notifications may not be a reliable way to mitigate or reduce PEM, new study in Nature Communications
· Small, phase one study is recruiting in Sacramento & San Francisco, CA to test advanced techniques in total body imaging to improve understanding of “tissue-level immune dysregulation” in the disease

https://thesicktimes.org/2026/02/17/research-updates-february-17/

#ResearchUpdates #COVID

· SARS-CoV-2 reinfections significantly increase the risk of #LongCOVID in children, a new National Institutes of Health (NIH) RECOVER study found
· A large cohort study found further evidence that people with #HIV have a significantly increased risk of Long COVID following SARS-CoV-2 infection
· An in-depth whole genome sequencing study called Sequence #MECFS and Long COVID is seeking to raise £20 million ($23.6 million USD) in funding

https://thesicktimes.org/2026/02/24/research-updates-february-24/

#ResearchUpdates #TheSickTimes

· Researchers identified high levels of cytokine interferon gamma (IFN-γ) as a potential biomarker for #LongCOVID
· Two new studies compare SARS-CoV-2’s long-term risks to those of the flu
· A small phase 1 clinical trial will test the safety of the cancer monoclonal antibody Pembrolizumab (Keytruda)

https://thesicktimes.org/2026/03/03/research-updates-march-3/

#ResearchUpdates #COVID

· A large retrospective cohort study found significant healthcare cost increases for #LongCOVID over five years
· A South Korean clinical trial evaluated metformin and ursodeoxycholic acid (UDCA) for Long COVID, but didn’t find either effective
· Two recent preprints share additional analysis from clinical trials seeking to address viral persistence

https://thesicktimes.org/2026/03/10/research-updates-march-10/

#ResearchUpdates #COVID

· Two recent prevalence studies showed the impact of #LongCOVID on Americans
· A small study shared as a preprint in bioXriv found SARS-C0V-2 spike protein in the gut tissues of people with Long COVID
· Researcher Dianna Arnoux-Whiteman was awarded a $45,000 grant to survey the effects of Long COVID in the Blackfeet Nation

https://thesicktimes.org/2026/03/17/research-updates-march-17/

#ResearchUpdates #TheSickTimes